Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.69 |
| ▸ | CTSK | P43235 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26818255 | 0.87 | CTSS (0.67) | CTSSCTSKCA2PSENENCAPN1 | |
| SCHEMBL13921024 | 0.87 | CTSS (0.67) | CTSSCTSKCA2PSENENCAPN1 | |
| SCHEMBL13921008 | 0.87 | CTSS (0.67) | CTSSCTSKCA2PSENENCAPN1 | |
| SCHEMBL13934284 | 0.87 | CTSK (0.67) | CTSSCTSKCA2PSENENCAPN1 | |
| SCHEMBL13934344 | 0.87 | CTSK (0.67) | CTSSCTSKCA2PSENENCAPN1 | |
| SCHEMBL5559974 | 0.87 | CTSK (0.67) | CTSSCTSKCA2PSENENCAPN1 | |
| SCHEMBL28969869 | 0.87 | CTSK (0.67) | CTSSCTSKCA2PSENENCAPN1 | |
| SCHEMBL16909078 | 0.86 | CTSS (0.70) | CTSSCTSKCA2PSENENCAPN1 | |
| SCHEMBL16921308 | 0.86 | CTSS (0.66) | CTSSCTSKCA2PSENENCAPN1 | |
| SCHEMBL16921307 | 0.86 | CTSS (0.70) | CTSSCTSKCA2PSENENCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466784-B2 | Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis | APICAL MOLECULAR BIOTECH CO., LTD. (TW) | 2025-11-11 | — | — | US | disclosed |
| EP-4136063-B1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | APICAL MOLECULAR BIOTECH CO LTD (TW) | 2025-10-22 | — | — | EP | disclosed |
| US-20230234912-A1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | APICAL MOLECULAR BIOTECH CO., LTD. (TW) | 2023-07-27 | — | — | US | disclosed |
| CN-115835860-A | Novel analogues of pterostilbene amino acids with carbonate for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis | 树顶分子生技股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234912-A1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | FABP1, GLS2, SLC1A5 | CTSS 1586/4885CTSK 2360/4885CA2 1312/4885 |
| US-12466784-B2 | Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis | FABP1, GLS2, SLC1A5 | CTSS 1661/4885CTSK 2286/4885CA2 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.